CurrentCapital BluecrossPolicy AHS - G2050

Cardiovascular Disease Risk Assessment

Defines which laboratory biomarkers and tests for assessing cardiovascular disease (CVD) risk are covered, limited, or not covered for members and describes clinical contexts in which testing is appropriate.

Policy Summary

PayerCapital Bluecross

PolicyCardiovascular Disease Risk Assessment

Policy CodePolicy AHS - G2050

Change TypeNo material change

Effective Date

Next Review DateDec 1, 2025

Key ActionObtain hs-CRP only when treatment decisions remain uncertain after ACC/AHA pooled cohort equations and confirm abnormal results with a repeat test at least two weeks later.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

ApoB coveredApoB covered

Lp(a) onceLp(a) lifetime

hs-CRP limitedhs-CRP limited

Multiple not coveredTests not covered

DefinedSimple lipid panel

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Cardiovascular Biomarker and Lipid Testing

Not Medically Necessary / Not Covered

The following tests and panels are considered NOT MEDICALLY NECESSARY / NOT COVERED for cardiovascular disease (CVD) risk assessment and management because evidence is insufficient to demonstrate clinical utility or impact on management.

ALL of the following

High-sensitivity cardiac troponin T (hs-cTnT) for outpatient CVD risk assessment
Does not meet coverage criteria for CVD risk assessment in the outpatient setting.
Homocysteine testing for CVD risk assessment
Does not meet coverage criteria; lowering homocysteine has not been shown to reduce CVD events.
Novel lipid and non-lipid biomarkers (including but not limited to apolipoprotein AI, apolipoprotein E, B-type natriuretic peptide, cystatin C, fibrinogen, leptin, LDL subclass, HDL subclass) for routine CVD risk assessment
These biomarkers do not have established clinical utility for routine risk stratification and therefore do not meet coverage criteria.
Serum intermediate density lipoproteins measurement for CVD risk assessment
Does not meet coverage criteria.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) measurement for routine CVD risk assessment
Does not meet coverage criteria; trials of Lp-PLA2 inhibitors did not demonstrate outcome benefit.
Measurement of long-chain omega-3 fatty acids in red blood cell membranes for CVD risk assessment
Does not meet coverage criteria for risk assessment.
Conventional (non–high-sensitivity) CRP testing for cardiovascular risk assessment
Does not meet coverage criteria; lacks sensitivity for cardiovascular risk stratification.
High-sensitivity CRP (hs-CRP) testing for indications other than those specified in coverage criteria (e.g., population-wide or routine screening)
Hs-CRP testing outside of the covered, guideline-aligned scenarios is not covered; CDC/AHA and other societies advise against population-wide screening.
Commercial cardiovascular risk panels or proprietary multi-marker risk profiles (comprehensive panels combining lipids, inflammatory, genetic, metabolic markers, or proprietary scores) for routine risk assessment
Routine use of commercial multi-marker panels is not supported due to unclear impact on clinical management and insufficient evidence of benefit.
Expanded lipid panels (particle sizing, NMR, LDL-P) as routine screening for cardiovascular disease
ASCP recommends against routine use of expanded lipid panels for screening; not covered for routine risk assessment.
All other tests for assessing CVD risk not explicitly listed as covered under the policy
Not covered due to lack of sufficient published evidence of benefit.

Applicable Procedure and Code Guidance

Listed laboratory and biomarker CPT/HCPCS codesmixed

82172	Apolipoprotein, each.
82610	Cystatin C.
83090	Homocysteine.
83695	Lipoprotein (a).
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2).
83700	Lipoprotein, blood; electrophoretic separation and quantitation.
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed.
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (e.g., by NMR), includes particle subclasses when performed.
83719	Lipoprotein, direct measurement; VLDL cholesterol.
83722	Lipoprotein, direct measurement; small dense LDL cholesterol.

1–10 of 20

1/2

Proprietary algorithm/advanced biomarker testsHCPCS

0308U	Cardiology (CAD), analysis of 3 proteins (hs-troponin, adiponectin, KIM-1) with clinical parameters, plasma, algorithm reported as risk score for obstructive CAD (HART CADCADhs®).
0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, TIMP-1, KIM-1) with clinical parameters, plasma, algorithm reported as a risk score.
0377U	Cardiology (cardiovascular disease), analysis of proteins with algorithm reported as risk score for major adverse cardiac event (HART CVE®).
0415U	Cardiovascular disease (ACS), multiprotein panel with clinical variables, algorithm reported as a 5-year risk score for ACS (SmartHealth Vascular Dx™).
0541U	Cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 HDL-bound apolipoproteins, algorithm reported with pCAD score (HDL Reverse Cholesterol Transport Panel).

Referenced coverage guidancemixed

CMS Lipid Testing

Reference to Medicare/NCD guidance on lipid testing (no explicit CPT/HCPCS codes listed in this section)

Elevated hs-CRP

Elevated hs-CRP (risk-enhancing)>= 2.0 mg/L

Confirmatory measurementObtain a second hs-CRP >=2 weeks after an abnormal initial result and record the average in mg/L

High relative risk threshold (CDC/AHA)>3.0 mg/L (considered high relative risk)

Persistently elevated primary hypertriglyceridemia

Persistently elevated primary hypertriglyceridemia>= 175 mg/dL

Severe hypertriglyceridemia note>= 500 mg/dL denotes severe hypertriglyceridemia (actionable for pancreatitis risk)

Provider Responsibilities, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization / Authorization Status

Prior authorization is not specified in this policy excerpt. There are frequency recommendations and limitations described for certain tests (see items below), but no explicit prior authorization or step therapy rules are defined in the policy text.

No prior authorization requirement is described in the policy.
No step therapy rules are described in the policy.

Denial Risk

Commercial/Proprietary Panels — Justification May Be Required

Some multi-marker or proprietary cardiovascular risk panels have uncertain clinical utility; commercial panels may require clinical justification and are at higher risk of payer scrutiny or denial when not supported by guideline-based indications.

Commercial risk panels reporting multiple markers or proprietary scores may require documentation of clinical utility and specific indication.

Background and Rationale

Cardiovascular risk assessment aims to estimate an individual's probability of future CVD events using traditional risk factors and laboratory tests. Typical tests include a simple lipid panel (total cholesterol, HDL‑C, LDL‑C, triglycerides) and calculation of 10‑year risk using pooled cohort equations; additional biomarker testing (e.g., ApoB, Lp(a), hs-CRP, natriuretic peptides) may be used selectively as risk‑enhancing information when guideline‑based risk estimation leaves treatment decisions uncertain.

Definitions and Key Terms

Simple lipid panel — components

Simple lipid panel componentsTotal cholesterol; HDL cholesterol; LDL cholesterol; Triglycerides

Additional reportsCalculated ratios such as total/HDL cholesterol may also be reported

ExclusionsApolipoproteins, lipoprotein particle number/size, and Lp(a) are not components of a simple lipid panel

Pooled cohort equations (PCEs) — definition and use

Pooled Cohort Equations (PCEs)ACC/AHA risk calculator estimating 10-year ASCVD risk using age, sex, race, smoking, BP, diabetes, and cholesterol; informs clinician-patient risk discussion

LimitationsPCE is powerful for population estimates but has limitations for individuals; may be supplemented by risk-enhancing factors

Policy Revision History

2018-?guideline_citation

USPSTF published a recommendation statement on risk assessment for cardiovascular disease with nontraditional risk factors, cited in references informing this policy's review of nontraditional biomarkers.

2019-01-01guideline_update

ESC/EAS guidelines referenced recommending use of ApoB and guidance on lipid-related risk assessment, supporting coverage criteria for ApoB in select clinical contexts.

2021-01-01guideline_update

Policy Summary

PayerCapital Bluecross

PolicyCardiovascular Disease Risk Assessment

Policy CodePolicy AHS - G2050

Change TypeNo material change

Effective Date

Next Review DateDec 1, 2025

Key ActionObtain hs-CRP only when treatment decisions remain uncertain after ACC/AHA pooled cohort equations and confirm abnormal results with a repeat test at least two weeks later.

SourceLink

On This Page

Context for apoB measurementApoB measurement may be considered when triglycerides are elevated (eg, >=175 mg/dL) to refine risk

Elevated apoB risk-enhancing threshold

Elevated apoB (risk-enhancing)>= 130 mg/dL

Clinical triggerConsider apoB when triglycerides are >=200 mg/dL or when LDL-C may be inaccurate

Correspondence to LDL-CApoB >=130 mg/dL corresponds approximately to LDL-C >=160 mg/dL

Elevated Lp(a)

Elevated Lp(a)>= 50 mg/dL or >= 125 nmol/L

Use caseMeasure Lp(a) to refine risk when family history of premature ASCVD or other risk-enhancing contexts present

Very high inherited level>180 mg/dL (>430 nmol/L) indicates very high inherited Lp(a) and lifetime high risk

Lp(a) 90th percentile approximate value

Lp(a) 90th percentile (approximate)≈39 mg/dL

Genetic determination noteSerum Lp(a) levels are highly genetically determined; population 90th percentile ~39 mg/dL

Measurement method cautionDensity gradient ultracentrifugation is standard; some ELISA methods may be affected by Apo(a) isoforms

NT-proBNP prognostic threshold

NT-proBNP prognostic threshold<= 1,000 pg/mL (associated with better outcomes in HFrEF when reduced to this level)

Clinical contextNT-proBNP used for prognosis and monitoring in heart failure; interpret in context of guideline-directed therapy

LimitationsWide interindividual variation (eg, lower levels in obesity); use serial measures for trend interpretation

EPA/AA ratio

EPA/AA ratio associated with fewer events>0.75 (associated with fewer major coronary events in a Japanese cohort)

ComponentsEPA = eicosapentaenoic acid; AA = arachidonic acid

Clinical applicationMay guide consideration of omega-3 status/personalized supplementation in select patients; evidence mixed

hs-CRP thresholds (ACC/AHA and CDC/AHA)

ACC/AHA risk-enhancing hs-CRP threshold>= 2.0 mg/L (considered a risk-enhancing factor)

CDC/AHA high relative risk threshold>3.0 mg/L (CDC/AHA workshop: high relative risk; obtain two measurements ~2 weeks apart and average)

Measurement practiceObtain two hs-CRP measurements (optimally two weeks apart) and average in mg/L; repeat if abnormal and evaluate for inflammation/infection

Lp(a) threshold as risk-enhancing factor

Lp(a) risk-enhancing threshold>= 50 mg/dL or >= 125 nmol/L

Indications to measureConsider Lp(a) with family history of premature ASCVD, premature ASCVD in patient, or when risk stratification is uncertain

Very high inherited level>180 mg/dL (>430 nmol/L) identifies very high lifetime inherited risk per ESC/EAS guidance

ApoB threshold

ApoB definitionApolipoprotein B is the major structural protein of LDL/VLDL; ApoB concentration estimates atherogenic particle number

ApoB risk threshold>= 130 mg/dL (risk-enhancing; corresponds approximately to LDL-C >=160 mg/dL)

Preferred useRecommended for risk assessment in high TG, diabetes, obesity, or very low LDL-C where LDL estimates may be inaccurate

LDL-C thresholds

LDL-C thresholds>= 190 mg/dL (severe hypercholesterolemia); >=160 mg/dL noted in select contexts

Screening/useLDL-C recommended for screening and on lipid therapy per NLA/ACC guidance

Actionable reportingReport LDL-C >=190 mg/dL as possible familial hypercholesterolemia; follow-up and management recommended

Triglycerides thresholds

Triglycerides thresholds>= 500 mg/dL (severe hypertriglyceridemia); >= 175 mg/dL noted for persistent primary hypertriglyceridemia

Clinical actionTG >=500 mg/dL should prompt management to reduce pancreatitis risk; persistent TG >=175 mg/dL is a risk-enhancing context

Monitoring intervalsObtain follow-up lipids 4-12 weeks after treatment change and every 3-12 months on stable therapy

hs-CRP / Lp(a) high thresholds

High hs-CRP and very high Lp(a)hs-CRP >3.0 mg/L (elevated relative risk); Lp(a) >180 mg/dL (>430 nmol/L) indicates very high inherited level

Clinical implicationThese high thresholds may prompt intensification of therapy or closer follow-up in selected patients

Measurement frequencyLp(a) measured once in a lifetime to detect very high inherited levels; hs-CRP measured twice and averaged

Triglycerides threshold (mmol/L)

Triglycerides threshold (mmol/L)> 1.5 mmol/L (threshold where non-HDL-C or apoB preferred over LDL-C)

Preferred parametersWhen TG >1.5 mmol/L, use non-HDL-C or apoB instead of LDL-C for initial screening and treatment targets

CCS treatment targetsNon-HDL-C target <2.6 mmol/L; apoB target <0.8 g/L in intermediate/high risk individuals

Not applicable

Not applicableNot applicable

Usage noteReserved placeholder for thresholds or items that do not apply to a specific test or context

Policy contextUsed where no numeric threshold or parameter is defined in the source material

Proprietary panel CPT/HCPCS codes listed (e.g., 0019M, 0052U, 0308U, 0309U, 0377U, 0415U, 0541U) can trigger additional review or prior authorization requests.

Note

Lipid Monitoring Frequency and When More Frequent Testing May Be Indicated

Frequency guidance for lipid monitoring and other tests is provided but not framed as an authorization mechanism; follow guideline and CMS recommendations when determining testing intervals and document rationale for more frequent testing.

General: Annual lipid panel is reasonable for long-term monitoring.
Initial treatment: Components of panel may be medically necessary up to six times in the first year for monitoring.
After stabilization: LDL or total cholesterol may be measured ~3 times yearly after treatment goals achieved.
More frequent testing may be indicated for marked elevations or when changing therapy.

Billing Rule

Check CMS and Applicable Government Coverage Guidance

When applying coverage decisions for Medicare members, reference current CMS NCDs/LCDs as government policy supersedes policy language where conflicts exist.

Use CMS lipid monitoring guidance (see CMS NCD quoted in policy) when adjudicating Medicare claims.
When state Medicaid coverage differs, follow applicable state policy for that member.

Denial Risk

Tests Likely to Be Denied (Coverage Exclusions)

Tests explicitly listed as not meeting coverage criteria are high denial risk when billed without a covered indication. Ensure documentation supports any exceptions based on guideline-endorsed risk-enhancing factors.

Tests likely to be denied: conventional CRP for CVD risk, hs-cTnT for outpatient CVD risk assessment, homocysteine, novel lipid/non-lipid biomarkers (apoAI, apoE, BNP, cystatin C, fibrinogen, leptin, LDL/HDL subclass), intermediate density lipoproteins, Lp-PLA2, long-chain omega-3 fatty acid RBC membrane testing, and other tests listed as 'DOES NOT MEET COVERAGE CRITERIA'.
Commercial multi-marker panels that include these noncovered analytes or proprietary scores are also at risk for denial without strong clinical justification.

Documentation Required

Clinical Indication Documentation Required

Document the clinical indication and rationale for testing. Provide supporting clinical data when ordering advanced or proprietary tests and for any testing outside routine frequency guidance.

Document specific clinical indication (examples: hypertriglyceridemia, diabetes, obesity/metabolic syndrome, familial dyslipidemia, on lipid therapy, suspected familial dysbetalipoproteinemia or combined hyperlipidemia).
For Lp(a): document one-time lifetime measurement rationale (age ≥18).
For hs-CRP: document use only when risk-based treatment decision is uncertain after PCE and include timing of confirmatory testing.

Note

No Specific Laboratory-Ordering or Documentation Procedure Specified

No procedural requirements for documentation of laboratory orders (e.g., specific forms or pre-authorization numbers) are specified in the policy; the policy focuses on evidence-based indications and frequency.

Policy does not specify an ordered test form or separate documentation process beyond standard medical record support for the clinical indication.
If payer prior authorization programs exist locally, follow payer-specific PA processes even if not described here.

Documentation Required

Lipid Test Reporting and Follow-up

Report lipid panel results with attention to desirable thresholds and highlight potentially actionable abnormalities to facilitate follow-up.

Ensure lab reports flag severe hypercholesterolemia (LDL-C ≥190 mg/dL) and severe hypertriglyceridemia (TG ≥500 mg/dL).
Include notation when non-HDL-C or apoB is preferred (see triglyceride guidance).

Documentation Required

Baseline Testing and hs-CRP Sequencing Protocol

Baseline lipid testing should be documented prior to initiating lipid-lowering therapy. For hs-CRP sequencing, follow the two-measurement protocol with timing and confirmation before classifying as persistently elevated.

Document baseline lipid panel before starting pharmacologic therapy.
hs-CRP protocol: one initial test; if abnormal, repeat ≥2 weeks later; if persistently elevated, consider annual monitoring.
When using hs-CRP to inform treatment in the 10%–20% 10-year risk group, document clinician-patient risk discussion.

Note

HIV Patient Evaluation and Monitoring Considerations

HIV-infected patients require specific monitoring cadence and a comprehensive history at ART initiation; lipid testing frequency recommendations differ from the general population.

Obtain comprehensive present and past medical history including CVD risk factors at initiation of HIV care.
Lipid panel: baseline before ART, repeat 1–3 months after starting/changing ART, then every 6–12 months if abnormal or with risk factors; otherwise routine screening cadence may apply.

Documentation Required

Support Documents to Cite When Justifying Tests

Support clinical decisions with cited guideline and review documents when ordering advanced tests or when tests fall outside routine coverage language.

Cite relevant guidance (ACC/AHA, NLA, CCS, CDC/AHA, CMS, HIV IDSA) in the medical record when justifying non-routine or proprietary testing.
When disputing a denial, reference the specific guideline passage or evidence supporting the clinical need.

Note

Preferred Lipid Parameter When Triglycerides Elevated

When triglycerides are elevated, prefer non-HDL-C or apoB as the primary lipid parameter for screening and treatment targets rather than LDL-C.

If TG >1.5 mmol/L, use non-HDL-C or apoB for initial screening and treatment targets (e.g., non-HDL-C <2.6 mmol/L or apoB <0.8 g/L in intermediate/high-risk individuals).
Document rationale when substituting non-HDL-C or apoB for LDL-C in reports and treatment plans.

Step Therapy

Therapy Context — Statins and Omega-3 References

Clinical practice recommendations and evidence about omega-3 and statin therapy inform monitoring and therapeutic decisions but do not create payer step therapy rules in this policy.

Therapy context: clinicians may use guideline-based escalation (statin initiation/intensification, addition of non-statin agents) informed by lipid results and risk-enhancing factors.
Policy does not impose step therapy requirements for lipid-lowering medications.

Note

Referral Consideration for Postpartum Patients with Pregnancy Complications

Consider referral to specialized postpartum cardiovascular or lipid clinics for women with pregnancy complications that increase later ASCVD risk; document referral rationale.

Screen with comprehensive lipid panel at least 12 weeks postpartum for affected women.
Refer to specialized postpartum cardiovascular health or lipid clinic when available to assist in decisions about lipid-lowering therapy.

Note

No Explicit Authorization/Denial Triggers Specified

No explicit authorization or denial triggers beyond the coverage statements are provided; use the policy's covered/ not-covered lists plus member benefits and government policy to determine coverage.

There are no unique administrative triggers described in the policy that automatically require prior authorization.
Use clinical indication, guideline alignment, and member-specific benefit rules to support coverage decisions.

Use caseUse PCE before considering additional biomarkers (eg, hs-CRP) when treatment decision remains uncertain

Apo B definition

Apo B definitionApolipoprotein B is the major protein in LDL and VLDL; concentration reflects total atherogenic particle number

FormsApoB-100 is present in LDL/VLDL; each LDL particle contains one ApoB-100 molecule

Clinical preferencePreferred when LDL-C may be inaccurate (eg, high TG, diabetes, obesity) to refine ASCVD risk

Apo A-I definition

Apo A-I definitionApolipoprotein A‑I is the primary structural protein of HDL and is measured alone or as an ApoB:ApoA‑I ratio to indicate atherogenic vs antiatherogenic particles

Clinical useLow Apo A‑I may be associated with increased CVD risk; often reported with ApoB

ReportingMay be used to calculate ApoB:ApoA‑I ratio for additional risk information

Lp(a) definition and 90th percentile note

Lp(a) definitionLipoprotein(a) is an LDL-like particle with strong genetic determination and modest independent CAD risk

90th percentile noteEstimated 90th percentile of population Lp(a) ≈39 mg/dL; very high inherited levels >180 mg/dL (>430 nmol/L)

Measurement recommendationConsider a single lifetime Lp(a) measurement in adults to identify very high inherited levels

BNP / NT-proBNP definition

BNP / NT-proBNP definitionNatriuretic peptides released with ventricular pressure/volume overload; established diagnostic and prognostic biomarkers for heart failure

Prognostic useNT-proBNP <=1,000 pg/mL associated with better outcomes in HFrEF when achieved during guideline-directed therapy

Clinical limitationsWide range of values across individuals; levels influenced by obesity and comorbidities; interpret with clinical context

Lp-PLA2 definition

Lp-PLA2 definitionLipoprotein-associated phospholipase A2 is an inflammatory enzyme expressed in atherosclerotic plaques and associated with vascular risk

Evidence noteProspective studies show independent association with CVD but inhibitors failed to improve outcomes in trials

Potential utilityMay have utility in symptomatic patients or select metabolic disease populations, but not routine screening

High-sensitivity cardiac troponin definition

High-sensitivity cardiac troponin (hs-cTn) definitionCardiac-specific proteins measured with high-sensitivity assays to detect myocardial injury; elevated levels associate with increased CVD and mortality risk

Risk stratificationhs-cTn improves risk stratification in older adults and community populations beyond traditional factors

Not routine outpatient screeninghs-cTnT for outpatient CVD risk assessment is not endorsed for routine use in this policy excerpt

Long-chain omega-3 fatty acids (EPA/DHA) definition

Long-chain omega-3 fatty acids (EPA/DHA)Polyunsaturated fatty acids (>=C20) including EPA and DHA; blood EPA/DHA levels may correlate with CHD event risk

EPA/AA ratio relevanceEPA/arachidonic acid ratio may be clinically relevant; >0.75 associated with fewer coronary events in one cohort

Trial evidenceRandomized trial results mixed; some trials show benefit while others do not; guidance varies by indication

hs-CRP definition and measurement note

hs-CRP definition and measurement noteHigh-sensitivity C-reactive protein measured twice (optimally two weeks apart) with the average reported in mg/L

Intended useReasonable as an adjunct to major risk factors to refine 10-year CHD risk (particularly when risk 10%-20%) but not for population screening

Action on abnormalIf abnormal, repeat and evaluate for sources of infection or inflammation before using for risk decisions

Lipoprotein(a) lifetime measurement recommendation

Lp(a) lifetime measurement recommendationMeasure Lp(a) once in an adult's lifetime to identify very high inherited levels (>180 mg/dL / >430 nmol/L)

RationaleLifetime measurement helps detect inherited high-risk individuals without routine repeat testing

Guideline sourcesRecommended by ESC/EAS and CCS guidance cited in policy

non-HDL-C / apoB preferred parameter when TG elevated

Non-HDL-C / apoB preference when TG elevatedWhen triglycerides exceed 1.5 mmol/L, use non-HDL-C or apolipoprotein B instead of LDL-C for initial screening and treatment target

CCS targets exampleCCS suggests non-HDL-C target <2.6 mmol/L or apoB <0.8 g/L for treatment targets in intermediate/high risk individuals

Practical implicationUse non-HDL-C or apoB to avoid inaccuracies in LDL-C estimation when TG are elevated

Lipoprotein(a) lifetime measurement (duplicate emphasis)

Lp(a) — lifetime measurement (fallback emphasis)Lp(a) should generally be measured once in an adult's lifetime to detect very high inherited levels; routine repeat testing is not recommended

Clinical triggersMeasure with premature ASCVD, family history of elevated Lp(a), refractory LDL-C despite therapy, or calcific aortic stenosis

Very high level definition>180 mg/dL (>430 nmol/L) denotes very high inherited risk

Coronary artery calcium (CAC) screening definition

Coronary artery calcium (CAC) screening definitionNoninvasive CT-based imaging to detect coronary calcification used selectively to refine ASCVD risk in asymptomatic adults

Indicated populationConsider for asymptomatic adults >=40 years at intermediate risk (eg, FRS 10%-20%) when treatment decisions are uncertain

Not routineNot recommended for routine use in high-risk, patients already on statin, or most low-risk adults per CCS/VA/DoD guidance

Lipoprotein(a) — additional definition/support from references

Lp(a) additional definition/supportLp(a) is a genetically determined LDL-like particle linked to ASCVD; population-level data show modest independent risk and guideline support for targeted measurement

Evidence baseEpidemiologic studies report increased hazard ratios starting at >=30 mg/dL and higher risk at >=50 mg/dL

Analytic cautionSome assay methods (ELISA) may be affected by Apo(a) isoforms; standardization important

Lp-PLA2 — additional definition/support from references

Lp-PLA2 additional definition/supportLp-PLA2 is an inflammatory enzyme produced in atherosclerotic plaques with prospective associations to CVD but therapeutic inhibition did not improve outcomes

Study supportCollaborative analyses and cohort studies demonstrate independent prediction of CVD events

Clinical roleMay have limited utility in symptomatic or metabolic disease populations but not recommended for routine screening

High-sensitivity cardiac troponin — additional definition/support from references

High-sensitivity cardiac troponin — additional supportHigh-sensitivity cardiac troponin assays detect myocardial injury at low concentrations and improve risk discrimination for CVD and mortality

Population dataElevated hs-cTn associated with higher incident CVD, HF, and mortality in community cohorts and older adults

Policy stancehs-cTnT for outpatient risk assessment is not supported as routine testing in this policy excerpt; use selectively per guidelines and clinical context

European Society of Cardiology (ESC) 2021 prevention guideline cited recommending against routine assessment of circulating biomarkers for CVD risk stratification and advising repeat risk assessment about every 5 years, which informed recommendations on limited use of novel biomarkers.

2023-12-14guideline_updateLatest

NICE updated its cardiovascular disease risk assessment and reduction guidance (NG238), cited in the policy references for evidence and guideline alignment.